The Davis Lab is part of the Section of Molecular Medicine in the Department of Radiation Oncology

Our mission is to improve the care of breast cancer patients through cutting-edge translational research at the interface of clinical oncology, cancer biology, molecular genetics, and translational genomics.

Our goal is to understand and exploit the immunogenic properties of tumor irradiation in integrating it with immunotherapy to improve cancer patient outcome.

We are interested in understanding the deregulation of epigenetic and transcriptional pathways in human disease and in finding small molecules with therapeutic potential to normalize these gene expression patterns. 

Please contact our team if planning neoadjuvant Adriamycin (doxorubicin), for enrollment in the HP Cardiotox Study.

We study how disseminated cancer cells survive and give rise to overt metastatic lesions.

We are working at the interface of nanotechnology, drug delivery, and tumor immunology

Our lab currently studies hypoxia, prolyl hydroxylase, and VHL signaling in cancer, especially breast and renal cell carcinomas.

My lab has a long-time interest in understanding the mechanisms of transcription and gene regulation in mammalian cells using initially cell-free systems reconstituted with purified gene-specific transcription factors, general cofactors, and components of the general transcription machinery to recapitulate transcriptional events in vitro. 

We focus on the discovery of targeted therapies for major drivers of cancer using protein chemistry, enzymology, structural biology, informatics and cell biology. Some of our favorite targets are RAS and kinase proteins.